Creating a New Paradigm
for Platelet Use and Availability
Cellphire Therapeutics has developed a process to stabilize platelets for years. We have the potential to transform transfusion medicine by ensuring that a platelet-based hemostatic to stop bleeding is available for all patients, whenever and wherever they are needed.
Cellphire has two investigational products in Phase 2 clinical trials, including Thrombosomes®, a platelet-based freeze-dried hemostatic, and Cryopreserved Platelets (CPP).